Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

NCT07463521 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT07463521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07463521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Recruiting
Start date
May 27, 2026
Completion date
January 22, 2029
Enrollment
120 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ocular myasthenia gravis